Absci Corporation Reports 2021 Results, Announces NVIDIA Partnership
Analysts at Berenberg Bank provided their views on Absci Corporation (NASDAQ:ABSI) following the company’s released 2021 results. Given the company is still in the early stages of scaling its portfolio of both discovery and cell line development (CLD) programs, the analysts believe their revenue estimates are conservative in the near term.
2021 and early 2022 saw the adoption of the company’s newly commercialized discovery capabilities and the execution of five new active programs in 2021, as previously guided. On the back of early adoption of the company’s discovery applications and its new NVIDIA collaboration to scale its own AI capabilities, the analysts maintain their $28 price target and Buy rating.
During NVIDIA’s GTC conference yesterday, the company announced its new partnership with NVIDIA, through which it will leverage NVIDIA’s computational power to scale its own AI models for therapeutic protein design and optimization.
| Symbol | Price | %chg |
|---|---|---|
| 207940.KS | 934000 | -0.32 |
| 068270.KS | 180400 | -6.15 |
| 196170.KQ | 301000 | -0.17 |
| 091990.KQ | 75900 | 0 |
